Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.86)
# 83
Out of 4,641 analysts
129
Total ratings
62.83%
Success rate
58.02%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Reiterates: Overweight | n/a | $4.64 | - | 4 | Oct 18, 2024 | |
| LBPH Longboard Pharmaceuticals | Downgrades: Neutral | n/a | $59.55 | - | 16 | Oct 14, 2024 | |
| SPRY ARS Pharmaceuticals | Reiterates: Overweight | $30 | $16.05 | +86.92% | 4 | Oct 8, 2024 | |
| FDMT 4D Molecular Therapeutics | Downgrades: Neutral | n/a | $8.51 | - | 3 | Sep 23, 2024 | |
| ALEC Alector | Reiterates: Overweight | n/a | $4.67 | - | 2 | Sep 17, 2024 | |
| ASND Ascendis Pharma | Maintains: Outperform | $191 → $205 | $127.69 | +60.55% | 1 | Sep 17, 2024 | |
| JANX Janux Therapeutics | Reiterates: Overweight | $100 | $51.75 | +93.24% | 4 | Sep 16, 2024 | |
| CRNX Crinetics Pharmaceuticals | Reiterates: Overweight | $90 | $58.40 | +54.11% | 6 | Sep 16, 2024 | |
| BBIO BridgeBio Pharma | Reiterates: Overweight | $70 | $24.45 | +186.30% | 9 | Sep 16, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Overweight | n/a | $19.95 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $71.94 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.92 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $20.00 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.34 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $88.19 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $172.75 | - | 4 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $1.03 | +1,356.31% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $45.40 | +16.74% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $10.95 | +110.05% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $41.66 | +56.02% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $38.42 | +56.17% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $17.59 | +269.53% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $4.03 | +1,140.69% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $75 | $35.61 | +110.62% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $2.21 | +126.24% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $2.58 | +326.36% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $115.08 | +12.96% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $941.39 | -19.27% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $8 | $1.26 | +534.92% | 3 | Sep 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $13.11 | +14.42% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $0.24 | +18,418.52% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $15.61 | +252.34% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.22 | +1,251.35% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.02 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.74 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $202.48 | +23.47% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $175 → $230 | $0.51 | +44,760.54% | 4 | Jun 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $65.17 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $38.42 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $6.43 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $26.08 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $6.44 | +241.88% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.63 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $69.98 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $187.88 | -49.44% | 1 | Aug 17, 2017 |
Zura Bio
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.64
Upside: -
Longboard Pharmaceuticals
Oct 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $59.55
Upside: -
ARS Pharmaceuticals
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $16.05
Upside: +86.92%
4D Molecular Therapeutics
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.51
Upside: -
Alector
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.67
Upside: -
Ascendis Pharma
Sep 17, 2024
Maintains: Outperform
Price Target: $191 → $205
Current: $127.69
Upside: +60.55%
Janux Therapeutics
Sep 16, 2024
Reiterates: Overweight
Price Target: $100
Current: $51.75
Upside: +93.24%
Crinetics Pharmaceuticals
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $58.40
Upside: +54.11%
BridgeBio Pharma
Sep 16, 2024
Reiterates: Overweight
Price Target: $70
Current: $24.45
Upside: +186.30%
Jasper Therapeutics
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.95
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $71.94
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.92
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.00
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.34
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $88.19
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $172.75
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $1.03
Upside: +1,356.31%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $45.40
Upside: +16.74%
Aug 13, 2024
Initiates: Overweight
Price Target: $23
Current: $10.95
Upside: +110.05%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $41.66
Upside: +56.02%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $38.42
Upside: +56.17%
Aug 6, 2024
Reiterates: Overweight
Price Target: $65
Current: $17.59
Upside: +269.53%
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $4.03
Upside: +1,140.69%
May 6, 2024
Reiterates: Overweight
Price Target: $75
Current: $35.61
Upside: +110.62%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $2.21
Upside: +126.24%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $2.58
Upside: +326.36%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $115.08
Upside: +12.96%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $941.39
Upside: -19.27%
Sep 23, 2022
Upgrades: Outperform
Price Target: $2 → $8
Current: $1.26
Upside: +534.92%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $13.11
Upside: +14.42%
Mar 25, 2021
Initiates: Outperform
Price Target: $45
Current: $0.24
Upside: +18,418.52%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $15.61
Upside: +252.34%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $2.22
Upside: +1,251.35%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $3.02
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $9.74
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $202.48
Upside: +23.47%
Jun 19, 2018
Upgrades: Outperform
Price Target: $175 → $230
Current: $0.51
Upside: +44,760.54%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $65.17
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $38.42
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $6.43
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $26.08
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $6.44
Upside: +241.88%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $8.63
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $69.98
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $187.88
Upside: -49.44%